SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher full-year revenue outlook, driven by stronger demand for Amtagvi and Proleukin, is fueling a sharp rally. Traders are celebrating the commercial momentum and debating whether heavy short interest is amplifying the move, while many point to upcoming cancer-treatment data as a further potential catalyst.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobiles new change-of-control severance policy has fueled buyout and strategic-partnership speculation, though traders emphasize that the filing is not evidence of an active deal and may be routine governance. The chatter is tempered by frustration over the lack of shipment or launch updates for the next BlueBird satellites.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Unconfirmed reports that Lundbeck is exploring an acquisition of Xeris have sparked takeover chatter and heavy trading, while Xeris has said it is not for sale. Traders are debating whether the denial rules out a deal or is negotiating posture, with some preferring the companys standalone growth and XP-8121 potential.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys rally is being linked to reassurance that Oracle remains committed to the Project Jupiter fuel-cell deal after a force-majeure notice raised concerns about project delays, alongside broader enthusiasm for AI data-center power demand. Traders are bullish on the rebound but debate the stocks steep valuation and volatility, with some viewing the move as momentum or short covering rather than a change in fundamentals.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICO shares are under heavy pressure after the FHFA moved to put VantageScore alongside FICO on a unified mortgage pricing grid, raising concerns that competition could erode FICOs long-standing mortgage-scoring advantage. Traders are divided between seeing a lasting threat to its pricing power and viewing the selloff as an overreaction or buying opportunity.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is under pressure as Treasury yields surge amid inflation concerns, expectations of further Fed tightening and worries about government borrowing. Traders are largely bearish on the bond selloff, though some see oversold conditions and argue a rebound may be near; they also debate whether higher yields will eventually weigh on stocks.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop next-generation 10 kV silicon-carbide semiconductors is the main focus, with bullish traders viewing it as technology validation and a potential defense and infrastructure opportunity. Others point out that it is a prototype program with undisclosed financial terms, debating whether the announcement can translate into near-term revenue as the shares gave back some of their initial gains.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Rising Treasury yields and expectations for further Fed hikes are weighing on rate-sensitive small caps, leaving IWM lagging large-cap tech amid weak market breadth. Traders largely discuss continued downside and put hedges, though some see oversold conditions as a possible setup for a rebound.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Pharvaris successful Phase 3 HAE prevention results have raised concern that its oral candidate could compete with BioCrysts ORLADEYO and weigh on its longer-term market share, prompting a sharp pullback. Traders disagree on the threats scale, pointing to Pharvaris development and launch timeline and BioCrysts established commercial base and navenibart pipeline as potential offsets.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

McCormick Readies for Q3 Earnings: What to Expect From MKC Stock?

McCormick heads into Q3 earnings with expected revenue growth, improving Consumer trends and Flavor Solutions momentum, while cost pressures remain.


PG's Baby Care Regains China Lead on Premium Innovation Momentum

Procter & Gamble's China Baby Care regains as premium innovation drives double-digit organic sales growth, share gains and a return to the No. 1 position.

EYE or CL: Which Is the Better Value Stock Right Now?

EYE vs. CL: Which Stock Is the Better Value Option?

Conagra Brands Readies for Q1 Earnings: What to Expect From CAG Stock?

Conagra Brands faces soft category trends, inflation and tariff-related costs in Q1, while productivity and brand support may have partly offset pressures.


Here's Why Colgate-Palmolive (CL) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Tom's of Maine Introduces Hydroxyapatite Toothpaste to Meet Rising Consumer Demand

Tom's of Maine Introduces Hydroxyapatite Toothpaste to Meet Rising Consumer Demand Tom's of Maine Introduces Hydroxyapatite Toothpaste to Meet Rising Consumer DemandPR NewswireKENNEBUNK, Maine, Sept. 23, 2026 Fluoride-free, anti-sensitivity toothpaste formulated with naturally derived Calcium...

PG vs. CL: Which Consumer Staples Giant Has Stronger Market Position?

Procter & Gamble and Colgate differ in portfolio breadth, category leadership, premiumization and digital investment as they defend consumer staples share.

Will Pricing Sustain Procter & Gamble as Volume Growth Stays Elusive?

PG faces a $1.4 billion after-tax earnings headwind in fiscal 2027 as rising costs, FX pressure and other factors weigh on margins.

Is General Mills Positioned for a Beat in Q1 Earnings Release?

General Mills' innovation, premium offerings and broader distribution efforts are set to support brand relevance, engagement and first-quarter performance.


Colgate-Palmolive Declares Regular Quarterly Dividend

The Board of Directors of Colgate-Palmolive Company (NYSE:CL) today declared a quarterly cash dividend of $0.53 per common share, payable on November 13, 2026, to shareholders of record on October 20, 2026. The Company has paid uninterrupted dividends on its common stock since 1895...

Colgate-Palmolive Co. engages in the manufacturing and distribution of consumer products. It operates through the Oral, Personal, and Home Care, and Pet Nutrition segments. The Oral, Personal, and Home Care segment includes toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other similar items. The Pet Nutrition segment offers specialty pet nutrition products manufactured and marketed by Hill’s Pet Nutrition. The company was founded by William Colgate in 1806 and is headquartered in New York, NY.

Colgate-Palmolive Co.

Colgate-Palmolive Explores Sale Of Softsoap, Irish Spring, Speed Stick Brands: Report

Equity

Bearish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Feed

News

Sentiment

Earnings

Fundamentals

Info

CL News